These results are consistent with previous findings in which scutellarin treatment has decreased the mRNA level of JAK2 in hepatocellular carcinoma cells [43], TQ treatment has downregulated STAT3 in gastric cancer cells [44], and dasatinib treatment has downregulated STAT5A and STAT5B in K562 CML cells [45]. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.